USA - NYSE:TEVA - US8816242098 - ADR
TEVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While TEVA is still in line with the averages on profitability rating, there are concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROIC | 10.49% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Altman-Z | 0.63 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.49 | ||
| Fwd PE | 7.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.2 | ||
| EV/EBITDA | 7.7 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:TEVA (10/27/2025, 12:39:06 PM)
19.55
+0.6 (+3.17%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.49 | ||
| Fwd PE | 7.04 | ||
| P/S | 1.35 | ||
| P/FCF | 25.2 | ||
| P/OCF | 16.13 | ||
| P/B | 3.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.7 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROCE | 13.29% | ||
| ROIC | 10.49% | ||
| ROICexc | 11.36% | ||
| ROICexgc | 49.13% | ||
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% | ||
| FCFM | 5.35% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Debt/EBITDA | 3.51 | ||
| Cap/Depr | 48.92% | ||
| Cap/Sales | 3.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 29.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 0.63 |
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
ChartMill assigns a valuation rating of 8 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 6 / 10.
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 7.49 and the Price/Book (PB) ratio is 3.29.
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.